Anzeige
Mehr »
Sonntag, 10.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PS5P | ISIN: US35104E1001 | Ticker-Symbol:
NASDAQ
08.08.25 | 21:59
5,620 US-Dollar
-2,77 % -0,160
1-Jahres-Chart
4D MOLECULAR THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
4D MOLECULAR THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur 4D MOLECULAR THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.08.Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts26
01.08.4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study14
01.08.4D Molecular Therapeutics stock soars after positive DME trial results7
01.08.Positive Studiendaten zu Augenmedikament treiben Aktie von 4D Molecular Therapeutics an2
01.08.Pre-market Movers: Namib Minerals, 4D Molecular Therapeutics, CCC Intelligent Solutions, Enovix, Psyence Biomedical502OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.25 A.M. ET).In the Green Namib Minerals (NAMM) is up over 108% at $8.26. 4D...
► Artikel lesen
01.08.4DMT's stock climbs as eye disease gene therapy patients keep jettisoning injections6
31.07.4D Molecular Therapeutics, Inc.: 4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update1334D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains...
► Artikel lesen
24.07.4D Molecular Therapeutics, Inc.: 4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists1
4D MOLECULAR THERAPEUTICS Aktie jetzt für 0€ handeln
11.07.4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants132EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
► Artikel lesen
03.07.What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics8
03.07.4DMT lays off 25% of workforce while accelerating phase 3 eye gene therapy timeline1
02.07.4D Molecular to layoff about 25% of workforce1
02.07.4D Molecular Therapeutics, Inc. - 8-K, Current Report1
02.07.4D Molecular Therapeutics, Inc.: 4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution1414FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 20274FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns...
► Artikel lesen
20.06.4D Molecular Therapeutics, Inc. - 8-K, Current Report2
16.05.4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants272EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
► Artikel lesen
09.05.4D Molecular Therapeutics GAAP EPS of -$0.86 misses by $0.02, revenue of $0.01M misses by $0.44M5
08.05.4D Molecular Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
08.05.4D Molecular Therapeutics, Inc. - 10-Q, Quarterly Report1
08.05.4D Molecular Therapeutics, Inc. - 8-K, Current Report-
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1